Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

571.05 -37.44 (-6.15%)
Delayed Quote Updated: 2:19 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it. 
Via Investor's Business Daily
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Prime Value Pick with Strong Fundamentals and Undervalued Potential ↗
UNITED THERAPEUTICS CORP (UTHR) is a top value stock with strong fundamentals—low P/E, high profitability, zero debt, and steady growth—making it a standout in biotech. 
Via Chartmill
News headline image
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
From United Therapeutics Corporation
Via Business Wire
News headline image
Forecasting The Future: 7 Analyst Projections For United Therapeutics ↗
 
Via Benzinga
News headline image
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Moderna (NASDAQ:MRNA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock with Impressive Fundamentals and 2 to Keep Off Your Radar
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Strong Candidate for GARP Investors ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy. 
Via Chartmill
News headline image
1 Value Stock with Impressive Fundamentals and 2 to Turn Down
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Potential Undervalued Biotech Stock ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a financially healthy biotech stock with strong profitability and an undervalued price. Its low P/E and high margins make it a candidate for value investors. 
Via Chartmill
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers growth at a reasonable price, with strong profitability, no debt, and a PEG ratio of 0.68. A solid pick for long-term investors. 
Via Chartmill
News headline image
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? ↗
11 large-cap stocks were worst performers last week: SJM, CHWY, IOT, UTHR, CVNA, APP, UAL, GRAB, EIX, LULU, MBLY. Analysts lower price forecasts. 
Via Benzinga
News headline image
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 to Keep Off Your Radar
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Biotech Stock With Strong Fundamentals and Attractive Valuation ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong profitability, zero debt, and an undervalued stock price, making it a candidate for value investors in the biotech sector. 
Via Chartmill
News headline image
Dow Gains 50 Points; US Small Business Optimism Index Rises In May ↗
 
Via Benzinga
Topics Stocks
News headline image
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia ↗
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
News headline image
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge ↗
Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics 
Via Benzinga
Topics Intellectual Property
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and a cheap valuation, making it a standout for GARP investors following Peter Lynch's strategy. 
Via Chartmill
News headline image
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Safe-and-Steady Stock on Our Buy List and 2 to Ignore
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>